Supplementary Online Content


eTable. Overall Use of Statin and Its Dose Intensity During Each Guideline Period

eFigure 1. Eligible Patients Not on Any Lipid-Lowering Therapy During Each Guideline Period

eFigure 2. Trends in the Use of Moderate-High Intensity Statin and Non-statin LLT in Patients ≥21 Years With ASCVD

eFigure 3. Trends in the Use of Moderate-High Intensity Statin and Non-statin LLT in Patients ≥21 Years With LDL-C ≥190 mg/dL

eFigure 4. Trends in the Use of Moderate-High Intensity Statin and Non-statin LLT in 40-75 Years Old Diabetic Patients With LDL-C 70-189 mg/dL and Without ASCVD

eFigure 5. Trends in the Use of Moderate-High Intensity Statin and Non-statin LLT in 40-75 Years Old Primary Prevention Cohort With 10 Year ASCVD Risk ≥7.5% and LDL-C 70-189 mg/dL, and Without Diabetes

eFigure 6. Trends in the Use of Moderate-High Intensity Statin and Non-statin LLT in 40-75 Years Old Primary Prevention Cohort With 10 Year FRS ≥10% and LDL-C ≥130 mg/dL or 10 Year FRS <10% and LDL-C ≥160 mg/dL

eFigure 7. Overall Use of LLT During Each Guideline Period in the ATP III Primary Prevention Cohort

This supplementary material has been provided by the authors to give readers additional information about their work.
### eTable. Overall Use of Statin and Its Dose Intensity During Each Guideline Period

<table>
<thead>
<tr>
<th>Cohorts</th>
<th>Any intensity statin</th>
<th>Low intensity statin</th>
<th>Moderate intensity statin</th>
<th>High intensity statin</th>
<th>Statin dose unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
</tr>
<tr>
<td>Overall group</td>
<td>70.9</td>
<td>75.9</td>
<td>7.2</td>
<td>7.7</td>
<td>39.0</td>
</tr>
<tr>
<td>ASCVD</td>
<td>71.4</td>
<td>76.2</td>
<td>7.1</td>
<td>7.7</td>
<td>39.2</td>
</tr>
<tr>
<td>Elevated LDL-C</td>
<td>59.2</td>
<td>60.9</td>
<td>7.5</td>
<td>6.9</td>
<td>32.6</td>
</tr>
<tr>
<td>Diabetes</td>
<td>63.8</td>
<td>67.0</td>
<td>10.5</td>
<td>10.3</td>
<td>38.4</td>
</tr>
<tr>
<td>ACC/AHA primary prevention</td>
<td>51.2</td>
<td>55.1</td>
<td>8.9</td>
<td>7.3</td>
<td>32.1</td>
</tr>
<tr>
<td>Without heart failure&lt;sup&gt;a&lt;/sup&gt;</td>
<td>50.8</td>
<td>55.2</td>
<td>8.7</td>
<td>7.2</td>
<td>31.8</td>
</tr>
</tbody>
</table>

<sup>a</sup>Among patients from the ACC/AHA primary prevention group

ACC/AHA = American College of Cardiology/American Heart Association, ASCVD = atherosclerotic cardiovascular disease, LDL-C = low-density lipoprotein cholesterol, LLT = lipid lowering therapy
**eFigure 1.** Eligible Patients Not on Any Lipid-Lowering Therapy During Each Guideline Period

ACC/AHA = American College of Cardiology/American Heart Association, ASCVD = atherosclerotic cardiovascular disease, LDL-C = low-density lipoprotein cholesterol

© 2017 American Medical Association. All rights reserved.
eFigure 2. Trends in the Use of Moderate-High Intensity Statin and Non-statin LLT in Patients ≥21 Years With ASCVD

Dashed line reflects transition period. Patient encounters before and after ACC/AHA guidelines were 2,369,562 and 2,331,640, respectively

ASCVD = atherosclerotic cardiovascular disease, LLT = lipid lowering therapy

© 2017 American Medical Association. All rights reserved.
**eFigure 3.** Trends in the Use of Moderate-High Intensity Statin and Non-statin LLT in Patients ≥21 Years With LDL-C ≥190 mg/dL

Dashed line reflects transition period. Patient encounters before and after ACC/AHA guidelines were 4,830 and 4,260, respectively.

**Legend:**
- Orange line: Moderate-High Intensity Statin
- Blue line: Non-Statin

**Notes:**
- LDL-C = low-density lipoprotein cholesterol
- LLT = lipid lowering therapy

© 2017 American Medical Association. All rights reserved.
eFigure 4. Trends in the Use of Moderate-High Intensity Statin and Non-statin LLT in 40-75 Years Old Diabetic Patients With LDL-C 70-189 mg/dL and Without ASCVD

Dashed line reflects transition period. Patient encounters before and after ACC/AHA guidelines were 27,511 and 21,387, respectively.

ASCVD = atherosclerotic cardiovascular disease, LDL-C = low-density lipoprotein cholesterol, LLT = lipid lowering therapy

© 2017 American Medical Association. All rights reserved.
eFigure 5. Trends in the Use of Moderate-High Intensity Statin and Non-statin LLT in 40-75 Years Old Primary Prevention Cohort With 10 Year ASCVD Risk ≥7.5% and LDL-C 70-189 mg/dL, and Without Diabetes

Dashed line reflects transition period. Patient encounters before and after ACC/AHA guidelines were 26,163 and 16,880, respectively.

ASCVD = atherosclerotic cardiovascular disease, LDL-C = low-density lipoprotein cholesterol, LLT = lipid lowering therapy

© 2017 American Medical Association. All rights reserved.
eFigure 6. Trends in the Use of Moderate-High Intensity Statin and Non-statin LLT in 40-75 Years Old Primary Prevention Cohort With 10 Year FRS ≥10% and LDL-C ≥130 mg/dL or 10 Year FRS <10% and LDL-C ≥160 mg/dL

Dashed line reflects transition period. Patient encounters before and after ACC/AHA guidelines were 4,599 and 3,949, respectively.

FRS = Framingham’s risk score, LDL-C = low-density lipoprotein cholesterol, LLT = lipid lowering therapy

© 2017 American Medical Association. All rights reserved.
eFigure 7. Overall Use of LLT During Each Guideline Period in the ATP III Primary Prevention Cohort

ATP III = Third Adult Treatment Panel for the Detection Evaluation and Treatment of High Blood Cholesterol in Adults, LLT = lipid lowering therapy

© 2017 American Medical Association. All rights reserved.